STRUCTURAL MRI OUTCOME PREDICTORS IN MCI

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 轻度认知功能障碍（MCI）是一种异质性疾病，具有多种病因、表现和结局。这项前瞻性研究将调查基线磁共振成像（MRI）标记物是否可以预测MCI向阿尔茨海默病（AD）的转化。我们认为，内嗅/海马旁、颞下和外侧、后扣带回和楔前灰质萎缩、海马萎缩和侧脑室扩大与3年内向AD的转化密切相关。我们将从已确定的可用受试者中招募90例MCI受试者。他们将接受基线高质量结构MRI扫描和年度临床和神经心理学测试。所提出的用于相应形态显式匹配的最先进的基于表面的算法将减少受试者间的变异性，并增加检测局部疾病影响的能力。该项目的长期目标是影响试验计划和患者选择的方法，并为MCI治疗试验建立一个强有力的替代标志物。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Mild cognitive impairment (MCI) is a heterogeneous condition with multiple etiologies, presentations, and outcomes. This prospective study will investigate whether baseline magnetic resonace imaging (MRI) markers can predict conversion of MCI to Alzheimer disease (AD). We propose that entorhinal/parahippocampal, inferior and lateral temporal, posterior cingulate and precuneal gray matter atrophy, hippocampal atrophy and lateral ventricle enlargement will strongly correlate with conversion to AD within 3 years. We will recruit 90 MCI subjects from identified available recources. They will receive a baseline high-quality structural MRI scan and yearly clinical and neuropsychological testing. The proposed state-of-the-art surface-based algorithms for explicit matching of corresponding morphology will reduce intersubject variability, and increase the power to detect localized disease effects. The long-term goal of this project is to influence the methods of trial planning and patient selection, and to establish a powerful surrogate marker for MCI therepeutic trials.